Stocks are edging higher on Wall Street, keeping the market on track for its third weekly gain in the last four ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

A new market analysis projects the global myelodysplastic syndrome (MDS) treatment market will grow from an estimated value ...

Gilead Sciences (NASDAQ:GILD) saw its stock climb in after-hours trading on Friday, following an upbeat quarterly performance ...

TruReach Inc., a local nonprofit located in DuBois, is one of six organizations in the United States which is a beneficiary of the Center for Disease Analysis Foundation ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences (NASDAQ:GILD) raises its 2025 sales and profit forecasts as HIV product demand grows. Q2 revenue and earnings beat expectations.

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...